Exabis Library
Welcome to the e-CCO Library!
DOP30: Identifying dietary factors and metabolites that may promote healthier Crohn Disease microbiome and mucosal transcriptomics signals as future targets using Diet-Omics
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP30: Long-term outcomes of Crohn’s perianal fistulas treatment: anti-TNF with surgical closure versus anti-TNF alone (PISA-II) - A patient preference RCT
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP30: Multi-‘omics profiling in patients with quiescent Inflammatory Bowel Disease identifies biomarkers predicting relapse
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
DOP30: Segmental vs extended colectomy for colorectal cancer in Crohn’s Disease: Results from a multi-centre retrospective comparative study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP31 Serum protein markers for early and differential IBD diagnosis validated by machine learning approaches
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP31: Development and validation of the IBD-REFER criteria: when should a general practitioner or paediatrician refer a patient for suspected IBD?
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP31: Development and validation of the IBD-REFER criteria: when should a general practitioner or pediatrician refer a patient for suspected IBD?
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
DOP31: Efficacy and safety of bone marrow-derived mesenchymal stem cells in refractory perianal fistulae in Crohn’s Disease: Results from a prospective monocentric study
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP31: Gene correlation network analyses reveal transcript modules and pathogenic mechanisms associated with resistance and response to ustekinumab therapy in Ulcerative Colitis
2024
ECCO'24 Stockholm
Tuesday, 30 April 2024, 5:03 PM
DOP31: Gut metabolomic and compositional signatures predict response to treatment with exclusive enteral nutrition in children with active Crohn's disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP31: Gut metabolomic and compositional signatures predict response to treatment with exclusive enteral nutrition in children with active Crohn’s disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 2:22 PM
DOP31: Management and outcome of postoperative Crohn’s Disease in the elderly as compared to young adults: Data from Eneida registry
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP32 Clinical and molecular characterisation of patients with durable response to ustekinumab induction therapy: Results from the UNIFI phase 3 studies in moderate-to-severe ulcerative colitis
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP32: Biologic treatment does not reduce the risk of postoperative peristomal pyoderma gangrenosum in Crohn’s Disease patients
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP32: CD226+TIGITneg expression identifies pathogenic inflammatory CD4+ memory T cells in severe Crohn’s Disease patients, opening up opportunities for patient-tailored treatment strategies.
2024
ECCO'24 Stockholm
Tuesday, 30 April 2024, 5:03 PM
DOP32: Crohn's disease stricture matrisome analysis reveals the anti-fibrotic activity of milk-fat globule-epidermal growth factor 8 (MFGE8)
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP32: Crohn’s disease stricture matrisome analysis reveals the anti-fibrotic activity of milk-fat globule-epidermal growth factor 8 (MFGE8)
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 2:22 PM
DOP32: Long-term outcomes of enterocutaneous fistula complicating Crohn’s Disease: The ECUFIT study from GETECCU
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP32: Withdrawal of thiopurines in Crohn’s disease treated with scheduled adalimumab maintenance: a prospective randomised clinical trial (DIAMOND2)
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP32: Withdrawal of thiopurines in Crohn’s disease treated with scheduled adalimumab maintenance: a prospective randomised clinical trial (DIAMOND2)
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1